This site is intended for healthcare professionals

The Lancet publishes results from phase III program evaluating Rinvoq in atopic dermatitis. - AbbVie.

Read time: 1 mins
Last updated:26th May 2021
Published:26th May 2021
AbbVie has announced The Lancet published primary analysis results from the pivotal global Phase III clinical trials – Measure Up 1, Measure Up 2 and AD Up – evaluating Rinvoq (upadacitinib) in adults and adolescents with moderate to severe atopic dermatitis who were candidates for systemic treatment.
Condition: Atopic Dermatitis (Eczema)
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest